Product Images Sumatriptan Succinate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Sumatriptan Succinate NDC 55700-846 by Quality Care Products, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image description - New Doc 2020 03 05 09.54.45 1
This is a description of Sumatriptan Succinate, a medication that comes in tablet form containing 100mg of the drug. The tablets are distributed by Care Products, LLC with a phone number provided. It includes a GTIN number and an NDC, which are identification codes used in the healthcare industry. The tablets come in a packet of nine, and are intended for prescription use only. It includes manufacturing information for Sun Pharmaceutical Industries in India, who distributed the medication through Orstmbutec in New Jersey.*
chemical-structure - chemical structure
Sumatriptan-figure-1 - sumatriptan figure 1
This is a figure displaying the estimated probability of achieving initial headache response within 4 hours of treatment using oral sumatriptan. The data is based on a pooled analysis of three clinical trials that provided evidence of efficacy. The probability of response is shown over time with different doses of sumatriptan, ranging from 25mg to 100mg. The figure is a Kaplan-Meier plot with patients who did not achieve response or took rescue medication within 240 minutes censored to 240 minutes.*
Sumatriptan-figure-2 - sumatriptan figure 2
The Figure 2 shows the probability of patients taking a second dose of Sumatriptan Succinate tablets or other medication to treat migraine over the 24 hours following the initial dose of study treatment. The data is obtained from pooled trials 1, 2, and 3, which includes patients who had no response to the initial dose. The Kaplan-Meier plot is based on data obtained in the 3 clinical controlled trials providing evidence of efficacy with patients not using additional treatments censored to 24 hours. No remedication was allowed within 2 hours postdose.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.